Grace Therapeutics, Inc. Retained Earnings
Grace Therapeutics, Inc. (GRCE) had Retained Earnings of -$244.27 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$244.27M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$228.48M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$227.30M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$224.99M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$244.27M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$228.48M 10-Q · filed 2026-08-13 |
| 2025-12-31 | -$227.30M 10-Q · filed 2026-02-12 |
| 2025-09-30 | -$224.99M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$224.05M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$220.69M 10-K · filed 2026-06-18 |
| 2024-12-31 | -$221.32M 10-Q · filed 2025-02-13 |
| 2024-09-30 | -$217.17M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$213.74M 10-Q · filed 2024-08-09 |
| 2024-03-31 | -$211.12M 10-K · filed 2025-06-23 |
| 2023-12-31 | -$207.95M 10-Q · filed 2024-02-12 |
| 2023-09-30 | -$205.56M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$202.29M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$198.27M 10-K · filed 2024-06-21 |
| 2022-12-31 | -$169.18M 10-Q · filed 2023-02-14 |
| 2022-09-30 | -$165.29M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$160.36M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$155.84M 10-K · filed 2023-06-23 |
| 2021-12-31 | -$151.93M 10-Q · filed 2022-02-14 |
| 2021-09-30 | -$148.16M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$149.14M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$146.02M 10-K · filed 2022-06-21 |
| 2020-12-31 | -$140.37M 10-Q · filed 2021-02-09 |
| 2020-09-30 | -$137.15M 10-Q · filed 2020-11-16 |
| 2020-06-30 | -$131.01M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$126.34M 10-K · filed 2021-06-22 |
| 2019-03-31 | -$100.83M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |